Document is current
Any future updates will be listed below
-
Authors
Damei, Isabelle https://orcid.org/0000-0001-6569-6027
Caidi, Aziza
Auclin, Edouard
Adam, Julien
Mella, Sébastien https://orcid.org/0000-0002-8679-5718
Hasan, Milena https://orcid.org/0000-0002-0879-7099
Tartour, Eric https://orcid.org/0000-0002-7323-468X
Robert, Caroline https://orcid.org/0000-0002-9493-0238
Corgnac, Stéphanie https://orcid.org/0000-0002-3014-9178
Mami-Chouaib, Fathia https://orcid.org/0000-0001-9685-6011
- License Information
-
More Information
Article History
Received: 26 August 2024
Accepted: 28 May 2025
First Online: 1 July 2025
Competing interests
: C.R is occasional consultant for Roche, BMS, MSD, Merck, Sanofi, Pierre Fabre, Biothera, CureVac and Novartis. E.T. is an occasional consultant for Moderna and speaker for MSD and BMS. J.A. is an occasional consultant for AstraZeneca, Bayer, BMS, MSD and Roche. The remaining authors declare no competing interests.
